Literature DB >> 14607856

Modern complement analysis.

Michael Kirschfink1, Tom E Mollnes.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14607856      PMCID： PMC262430          DOI： 10.1128/cdli.10.6.982-989.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  73 in total

1.  Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.

Authors:  G Zilow; J A Sturm; U Rother; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

2.  Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a.

Authors:  K Bergh; O J Iversen
Journal:  Scand J Immunol       Date:  1989-03       Impact factor: 3.487

3.  Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.

Authors:  T E Mollnes; P Garred; G Bergseth
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

4.  Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.

Authors:  C E Hack; J H Nuijens; R J Felt-Bersma; W O Schreuder; A J Eerenberg-Belmer; J Paardekooper; W Bronsveld; L G Thijs
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

5.  Hereditary and acquired complement deficiencies in animals and man. Introduction.

Authors:  K Rother; U Rother
Journal:  Prog Allergy       Date:  1986

6.  Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex.

Authors:  T E Mollnes
Journal:  Complement       Date:  1985

7.  Plasma C3d/C3 quotient as a parameter for in vivo complement activation.

Authors:  W Nürnberger; S Bhakdi
Journal:  J Immunol Methods       Date:  1984-11-16       Impact factor: 2.303

8.  A comparative study of complement activation.

Authors:  D A Higgins; D J Langley
Journal:  Vet Immunol Immunopathol       Date:  1985-05       Impact factor: 2.046

9.  Assay of complement activity in human serum using large unilamellar liposomes.

Authors:  T Masaki; N Okada; R Yasuda; H Okada
Journal:  J Immunol Methods       Date:  1989-09-29       Impact factor: 2.303

10.  Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat.

Authors:  M Schulze; P J Baker; D T Perkinson; R J Johnson; R F Ochi; R A Stahl; W G Couser
Journal:  Kidney Int       Date:  1989-01       Impact factor: 10.612
View more
  22 in total

Review 1.  Viral-derived complement inhibitors: current status and potential role in immunomodulation.

Authors:  Hadi Abou-El-Hassan; Hassan Zaraket
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-26

2.  Production of Staphylococcal Complement Inhibitor (SCIN) and Other Immune Modulators during the Early Stages of Staphylococcus aureus Biofilm Formation in a Mammalian Cell Culture Medium.

Authors:  Andi R Sultan; Jasper W Swierstra; Nicole A Lemmens-den Toom; Susan V Snijders; Silvie Hansenová Maňásková; Annelies Verbon; Willem J B van Wamel
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

3.  Importance of the Complement Alternative Pathway in Serum Chemotactic Activity During Sepsis.

Authors:  Ganqiong Xu; Yan Feng; Dan Li; Qichang Zhou; Wei Chao; Lin Zou
Journal:  Shock       Date:  2018-10       Impact factor: 3.454

Review 4.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

5.  Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells.

Authors:  Ravi Maruvada; Anna M Blom; Nemani V Prasadarao
Journal:  Immunology       Date:  2007-11-20       Impact factor: 7.397

6.  Inhibitors of C5 complement enhance vaccinia virus oncolysis.

Authors:  D Magge; Z S Guo; M E O'Malley; L Francis; R Ravindranathan; D L Bartlett
Journal:  Cancer Gene Ther       Date:  2013-05-10       Impact factor: 5.987

7.  Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease.

Authors:  Kristina N Ekdahl; Dan Norberg; Anders A Bengtsson; Gunnar Sturfelt; Ulf R Nilsson; Bo Nilsson
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

8.  Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Eveline Y Wu; Elizabeth A McInnis; Sonia Boyer-Suavet; Carmen E Mendoza; Lydia T Aybar; Kristin B Kennedy; Caroline J Poulton; Candace D Henderson; Yichun Hu; Susan L Hogan; Peiqi Hu; Hong Xiao; Patrick H Nachman; J Charles Jennette; Ronald J Falk; Donna O Bunch
Journal:  Arthritis Rheumatol       Date:  2019-10-08       Impact factor: 10.995

9.  Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

Authors:  Nuzhat Maisha; Tobias Coombs; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2020-07-06

Review 10.  Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.

Authors:  Franca Iorember; Anjali Nayak
Journal:  Pediatr Nephrol       Date:  2020-06-12       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.